- Home
- ACP vs IVA Comparison
ACP vs IVA Comparison
Compare ACP & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACP
- IVA
- Stock Information
- Founded
- ACP 2010
- IVA 2011
- Country
- ACP United States
- IVA France
- Employees
- ACP N/A
- IVA N/A
- Industry
- ACP Investment Managers
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- ACP Finance
- IVA Health Care
- Exchange
- ACP Nasdaq
- IVA Nasdaq
- Market Cap
- ACP 740.3M
- IVA 769.0M
- IPO Year
- ACP N/A
- IVA 2020
- Fundamental
- Price
- ACP $5.92
- IVA $5.46
- Analyst Decision
- ACP
- IVA Strong Buy
- Analyst Count
- ACP 0
- IVA 6
- Target Price
- ACP N/A
- IVA $15.33
- AVG Volume (30 Days)
- ACP 337.9K
- IVA 71.5K
- Earning Date
- ACP 01-01-0001
- IVA 09-26-2025
- Dividend Yield
- ACP 17.79%
- IVA N/A
- EPS Growth
- ACP N/A
- IVA N/A
- EPS
- ACP N/A
- IVA N/A
- Revenue
- ACP N/A
- IVA $14,591,573.00
- Revenue This Year
- ACP N/A
- IVA $80.35
- Revenue Next Year
- ACP N/A
- IVA N/A
- P/E Ratio
- ACP N/A
- IVA N/A
- Revenue Growth
- ACP N/A
- IVA N/A
- 52 Week Low
- ACP $5.55
- IVA $1.53
- 52 Week High
- ACP $7.17
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- ACP 48.04
- IVA 58.24
- Support Level
- ACP $5.94
- IVA $5.21
- Resistance Level
- ACP $5.94
- IVA $5.78
- Average True Range (ATR)
- ACP 0.03
- IVA 0.35
- MACD
- ACP -0.00
- IVA -0.03
- Stochastic Oscillator
- ACP 43.75
- IVA 47.09
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.